Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00149058
Status:
UNKNOWN
Last Update Posted:
2005-09-08
First Post:
2005-09-06
Brief Title:
Erythropoietin in Acute Myocardial Infarction
Sponsor:
Hammersmith Hospitals NHS Trust
Organization:
Hammersmith Hospitals NHS Trust
Study Overview
Official Title:
A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction
Status:
UNKNOWN
Status Verified Date:
2005-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Erythropoietin EPO is a naturally occuring hormone which regulates the bodys response to lack of oxygen and controls the number of red cells in the blood Recent studies in animals have shown that EPO has protective effects when organs such as the heart and brain are injured by lack of oxygen due to reduced blood supply
We wish to test the idea that giving a patient who is having a heart attack an injection of EPO will reduce the size of the heart attack
We wish to test the idea that giving a patient who is having a heart attack an injection of EPO will reduce the size of the heart attack
Detailed Description:
We wish to perform a randomised double-blind placebo-controlled clinical trial to examine the effects of EPO given at the time of primary angioplasty for acute myocardial infarction MI on myocardial infarct size In this trial the null hypothesis is that there is no effect of EPO on myocardial infarct size the alternative hypothesis is that EPO reduces myocardial infarct size
124 subjects with acute ST-elevation MI who fulfil the inclusionexclusion criteria and give informed consent to participate in the study will be recruited from patients referred to the cardiac catheterisation laboratories at the Hammersmith Hospital and Kings College Hospital Subjects will undergo primary percutaneous coronary angioplasty primary PCI according to standard clinical protocols Subjects will be randomised to either placebo or EPO at the time of primary PCI EPO will be given as a bolus of 12ml containing 33000U over 30 mins via a peripheral vein followed by an infusion of 24ml containing 67000 U over 12 hours Placebo will be identical to EPO without the active ingredient After the PCI subjects will receive standard care on the coronary care unit An additional 20ml of blood will be taken each day at the time of routine clinical venesection for storage and subjects will have gadolinium enhanced cardiovascular magnetic resonance CMR performed before discharge to evaluate infarct size Follow-up will be performed at 30 days clinical ECG and 20ml blood sample and at 90 days clinical ECG and CMR scan and blood sample The study will end at 90 days and patients will continue with standard clinical care under the direction of a consultant cardiologist
CMR will be performed in the Robert Steiner MR UnitImaging Department Hammersmith Hospital using a 15 tesla scanner according to standard protocols Each scan will last about 1h and information will be collected on tissue characteristics left ventricular function wall motion abnormalities myocardial perfusion Myocardial infarcts will be detected by late contrast gadolinium enhancement Gadolinium will be used at doses up to 02mmolkg and is safe with an incidence of mild and transient side effects including headache and nausea of 1 Scans will be performed with under continuous ECG monitoring with a doctor and at least 1 other person present Resuscitation facilities will be available at all times and the MRI facility is covered by an experienced 24 hour a day cardiac arrest team
124 subjects with acute ST-elevation MI who fulfil the inclusionexclusion criteria and give informed consent to participate in the study will be recruited from patients referred to the cardiac catheterisation laboratories at the Hammersmith Hospital and Kings College Hospital Subjects will undergo primary percutaneous coronary angioplasty primary PCI according to standard clinical protocols Subjects will be randomised to either placebo or EPO at the time of primary PCI EPO will be given as a bolus of 12ml containing 33000U over 30 mins via a peripheral vein followed by an infusion of 24ml containing 67000 U over 12 hours Placebo will be identical to EPO without the active ingredient After the PCI subjects will receive standard care on the coronary care unit An additional 20ml of blood will be taken each day at the time of routine clinical venesection for storage and subjects will have gadolinium enhanced cardiovascular magnetic resonance CMR performed before discharge to evaluate infarct size Follow-up will be performed at 30 days clinical ECG and 20ml blood sample and at 90 days clinical ECG and CMR scan and blood sample The study will end at 90 days and patients will continue with standard clinical care under the direction of a consultant cardiologist
CMR will be performed in the Robert Steiner MR UnitImaging Department Hammersmith Hospital using a 15 tesla scanner according to standard protocols Each scan will last about 1h and information will be collected on tissue characteristics left ventricular function wall motion abnormalities myocardial perfusion Myocardial infarcts will be detected by late contrast gadolinium enhancement Gadolinium will be used at doses up to 02mmolkg and is safe with an incidence of mild and transient side effects including headache and nausea of 1 Scans will be performed with under continuous ECG monitoring with a doctor and at least 1 other person present Resuscitation facilities will be available at all times and the MRI facility is covered by an experienced 24 hour a day cardiac arrest team
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None